Quietmind Foundation

  • About
  • Services
    • Medical Marijuana
  • Clinical Trials
    • Light Therapy for Dementia
    • Vielight Clinical Trial
    • Cosmetic Study of Wrinkles
  • Research
  • Equipment
  • Blog

Leading Edge Commentary

Sleep Really is Neuroprotective

6/19/2019

0 Comments

 
Picture
New blood markers that reflect risk for Alzheimer’s disease (AD) are uncovering important modifiable risk factors to be aware of to dramatically reduce the likelihood of ever suffering from this cruel disease. The latest study shows that just one night of sleep disruption is associated with an increase in these blood markers.

The primary brain lesions of AD are the result of deposits of a substance known as beta-amyloid. Although the immune cells in the brain normally remove beta-amyloid and plaque, research is beginning to characterize a chronic and excessive inflammatory reaction to amyloid proteins in the brain in susceptible individuals that can promote AD. Blood measurements of a protein called tau that is formed from toxic beta-amyloid as well as a protein that acts as the internal skeleton of brain cells known neurofilament light chain (NfL) protein can predict neurodegeneration years before clinical symptoms appear in AD. When brain cells are damaged, tau and NfL are released into cerebrospinal fluid and then the blood.

Background Data:
Poor sleep quality is associated with a significant risk for Alzheimer’s disease. For example, researchers from the Washington University School of Medicine in St. Louis found that the inability to sleep through the night was associated with an increased risk the preclinical form of Alzheimer’s disease. Subjects who were the least efficient sleepers in the study were five times more likely to have preclinical form of Alzheimer's. While researchers are exploring the formation of the beta-amyloid as being the cause of the poor sleep quality, a more likely explanation is that the poor sleep quality is actually the cause of the beta-amyloid formation.
​

During the deeper levels of sleep the repair mechanisms and antioxidant system of brain cells are heightened. Sleeping pills seem to exacerbate this situation. Use of sedative hypnotic drugs (sleeping pills) was associated with a whopping 230% increase risk of AD over an eight-year period in a study in France while in a study in the U.K., the risk was even greater over a 22-year follow up study– a dramatic 294% increase. The link between sleeping pill usage and the dramatic increased risk for AD may be the result of the fact that these drugs typically negatively impact the ability to achieve deeper levels of sleep.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    QMF News

    Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general. 

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    June 2019
    May 2019
    April 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    March 2018
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    May 2017

    Categories

    All
    Alzheimer's
    Biofeedback
    Breathing Training
    Dementia
    Dementia Treatment
    Drug Free Anxiety Treatment
    Infrared Light
    Light Therapy
    Neurofeedback
    Neurotherapy
    Panic Disorder
    Photobiomodulation
    Relaxation
    TBI Treatment
    Therapy

    RSS Feed

Our mission is to study, provide and promote drug-free, low-cost, noninvasive approaches to understanding and treating disorders that affect people's thinking, behavior, and movement.


Office Hours

Monday & Thursday: 11am - 6pm
In-office and
​remote conferencing available

Locations

Main Office- PA
​8120 Old York Road, Suite 140
Elkins Park, PA 19027

New York Office
1619 3rd Ave. Suite 202 New York, NY 10128
​
(clinical trial evaluation only)

Telephone Number

610-940-0488

Fax Number

215-359-0630

Email

info@quietmindfdn.org

Support Us

QuietMIND Foundation is a 501c3 charitable nonprofit. Donations are fully tax deductible. We work to provide services regardless of ability to pay, please help those who need help.
© 2020 Quietmind Foundation | All Rights Reserved | Quietmind Foundation is a not-for-profit 501(c)(3) organization.
  • About
  • Services
    • Medical Marijuana
  • Clinical Trials
    • Light Therapy for Dementia
    • Vielight Clinical Trial
    • Cosmetic Study of Wrinkles
  • Research
  • Equipment
  • Blog